Dec 27 (Reuters) - Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer. (Reporting by Christy Santhosh; Editing by Shailesh Kuber)